Description: Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Home Page: www.corvuspharma.com
CRVS Technical Analysis
863 Mitten Road
Burlingame,
CA
94010
United States
Phone:
650 900 4520
Officers
| Name | Title |
|---|---|
| Dr. Richard A. Miller M.D. | Co-Founder, Pres, CEO & Chairman |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Director |
| Mr. Leiv Lea | Chief Financial Officer |
| Dr. William Benton Jones Ph.D. | Sr. VP of Pharmaceutical Devel. |
| Dr. Erik J. Verner Ph.D. | Co-Founder |
| Dr. James T. Rosenbaum M.D. | Sr. VP of Research |
| Mr. Alan C. Mendelson Esq. | Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.576 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-03-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |